On January 27, 2022 TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), reported that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET (Press release, TYME, JAN 27, 2022, View Source [SID1234607456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financial Officer, will host a conference call and webcast as follows:

The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.

Following the Company’s presentation, there will be a Q&A session. Management will address both live questions and those submitted in advance via email to [email protected]. The deadline to submit questions for the conference call is 5:00 PM ET on February 7, 2022.

On January 27, 2022 The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), reported that declared a regular quarterly dividend of $0.07 per share of common stock January 27, 2022 (Press release, PerkinElmer, JAN 27, 2022, View Source [SID1234607440]). This dividend is payable on May 13, 2022 to all shareholders of record at the close of business on April 22, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 27, 2022 Johnson & Johnson (NYSE: JNJ) reported that it will participate in Citi’s 2022 Virtual Healthcare Conference on Wednesday, February 23rd, Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time) (Press release, Johnson & Johnson, JAN 27, 2022, View Source;johnson-to-participate-in-citis-2022-virtual-healthcare-conference-301470256.html [SID1234607457]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at www.investor.jnj.com.

A webcast and podcast replay will be available approximately 48 hours after the live webcast.

On January 27, 2022 EORTC reported The MINDACT (EORTC 10041/BIG3-04) study, a multicentre, randomised phase 3 clinical trial, aims to identify those women with early-stage breast cancer who can be spared chemotherapy after surgery through the use of a genomic and clinical risk assessment. Between 2007 and 2011, 6693 patients aged 18 to 70 whose cancer had either not spread to the lymph nodes under the arm, or to no more than three nodes, were enrolled to the trial, which was carried out in 112 institutions in nine European countries (Press release, EORTC, JAN 27, 2022, View Source [SID1234607424]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The latest sub-group analysis, published recently in the Journal of Clinical Oncology* looked at the 15% of patients who had an ultra-low genomic risk of recurrence based on the 70-gene signature MammaPrint. After a median follow-up of 8.7 years, 99% of these patients had not died from their disease, and their risk of cancer spreading to other parts of the body (distant metastasis) was significantly less than for patients with low-risk tumours. Patients with ultra-low risk tumours had an excellent prognosis regardless of the result of their clinical risk assessment.

Of the ultralow-risk patients, 67% were aged 50 years or more, and 99% were estrogen receptor (ER)-positive. Systemic therapy was received by 84% of patients (69% endocrine therapy (ET), 14% endocrine therapy plus chemotherapy, 1% other) and 16% received no adjuvant systemic treatment.

"Although trials have shown that gene signatures can be used to identify subgroups of patients who can safely be spared chemotherapy, current guidelines still include the use of ET in all hormone receptor positive patients, even those at very low risk" said Dr Josephine Lopes Cardozo, from the Netherlands Cancer Institute and EORTC. "ET side effects are often underestimated, and, as a result, adherence to the treatment is poor, with only half of all patients finishing a five-year course. Our analysis of ultra-low risk patients shows that these patients might be candidates for further reduction of treatments such as ET."

The investigators hope that the ultra-low risk gene signature will be used in future trials investigating the de-escalation of ET in order to achieve a better balance between benefit and harm. Findings from earlier studies have suggested that the introduction of population-based screening programmes has led to an increase of tumours with low-risk and ultra-low risk molecular profiles, and that these are over-represented within screen-detected cancers. "Being able to identify these patients who may have a limited benefit from ET could help to personalize treatment by reducing treatment durations or completely omitting ET and ultimately preventing overtreatment," says Dr Lopes Cardozo. "This would have benefits not only for patients, but also save money for healthcare systems."

On January 27, 2022 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neurodegenerative disease, reported that the company entered into a stock purchase agreement before the market close on January 27, 2022 with a syndicate of new and existing investors for a private placement of 5,945,943 shares of common stock at a purchase price of $1.11 per share for aggregate gross proceeds of approximately $6.6 million (Press release, Vaccinex, JAN 27, 2022, View Source [SID1234607441]). The private placement is expected to close on January 31, 2022, subject to customary closing conditions. No warrants, derivatives, or financial covenants are associated with the purchase agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants in the private placement include entities controlled by Dr. Maurice Zauderer, President and CEO of Vaccinex , and Albert D. Friedberg, Chairman of Vaccinex’s board of directors, each of which purchased $2 million worth of shares, as well as an entity controlled by Jacob Frieberg, another member of Vaccinex’s board of directors, and additional new and existing shareholders that are unaffiliated with Vaccinex, that together purchased the remaining $2.6 million worth of shares.

Vaccinex intends to use the net proceeds from the private placement to fund the ongoing development of its lead drug candidate, pepinemab, in cancer and neurodegenerative disease and for working capital and general corporate purposes.

Vaccinex also announced that during the month of January, prior to entering into the stock purchase agreement, Vaccinex sold approximately $3.5 million of shares of its common stock in January 2022 for a weighted average sales price of $1.16 per share under its existing open market sales agreement with Jefferies, LLC. This brings the total of new equity financing to date in 2022 to $10.1 million.

In connection with the private placement, Vaccinex will also enter into a registration rights agreement with certain of the private placement investors. Pursuant to the registration rights agreement, Vaccinex will agree to, among other things, use its reasonable best efforts to file with the Securities and Exchange Commission (the SEC) a registration statement covering the resale of the shares.

A description of the stock purchase agreement and registration rights agreement will be included in a Form 8-K to be filed with the SEC.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale are unlawful. Any offering of the securities under the resale registration statement will only be by means of a prospectus.